Renaissance Technologies LLC lessened its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 41.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,200 shares of the company’s stock after selling 7,900 shares during the quarter. Renaissance Technologies LLC’s holdings in Stoke Therapeutics were worth $151,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quest Partners LLC acquired a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at $29,000. Nisa Investment Advisors LLC grew its holdings in shares of Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Stoke Therapeutics in the second quarter valued at approximately $123,000. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics in the 1st quarter valued at approximately $141,000. Finally, BNP Paribas Financial Markets boosted its position in Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after buying an additional 6,636 shares during the period.
Insider Activity
In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.30% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on STOK
Stoke Therapeutics Stock Performance
Stoke Therapeutics stock opened at $11.84 on Monday. The stock has a market capitalization of $617.11 million, a price-to-earnings ratio of -4.91 and a beta of 0.97. Stoke Therapeutics, Inc. has a 52-week low of $3.35 and a 52-week high of $17.58. The stock’s 50 day moving average price is $13.79 and its two-hundred day moving average price is $13.72.
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The business had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. On average, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.1 EPS for the current year.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
See Also
- Five stocks we like better than Stoke Therapeutics
- Where Do I Find 52-Week Highs and Lows?
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- How to Effectively Use the MarketBeat Ratings Screener
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- How to Choose Top Rated Stocks
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.